Description

Satralizumab is a monoclonal antibody used in the treatment of neuromyelitis optica spectrum disorder (NMOSD). It works by inhibiting the activity of interleukin-6, which plays a role in the inflammatory process associated with this condition.

Interpreter Notes

Interpreters should be aware that satralizumab may be referred to in various ways in clinical settings, but the term 'satralizumab' is the preferred reference. It's important to maintain a formal register and avoid colloquial terms that may arise in patient discussions.

Example Sentences

EN: The doctor prescribed satralizumab to manage the patient's neuromyelitis optica spectrum disorder.

ES: El médico recetó satralizumab para manejar el trastorno del espectro de neuromielitis óptica del paciente.

Common Interpreter Mistakes

Confusing satralizumab with similar-sounding medications; using informal language instead of clinical terminology; misidentifying the condition it treats.